Immunosuppressants against acute kidney injury: what to prefer or to avoid?

References

• Sawhney S, Bell S, Black C, et al. Harmonization of epidemiology of acute kidney injury and acute kidney disease produces comparable findings across four geographic populations. Kidney Int. 2022;101(6):1271–1281. doi:10.1016/j.kint.2022.02.033.
   PubMed Web of Science ®Google Scholar
• Patel M, Heipertz A, Joyce E, et al. Acute kidney disease predicts chronic kidney disease in pediatric non-kidney solid organ transplant patients. Pediatr Transplant. 26(6):e14172. doi:10.1111/petr.14172.
   PubMed Web of Science ®Google Scholar
• Fiorentino M, Bagagli F, Deleonardis A, et al. Acute kidney injury in kidney transplant patients in intensive care unit: from pathogenesis to clinical management. Biomedicines. 2023;11(5):1474. doi:10.3390/biomedicines11051474.
   PubMed Web of Science ®Google Scholar
• Anders H-J, Wilkens L, Schraml B, et al. One concept does not fit all: the immune system in different forms of acute kidney injury. Nephrol Dial Transplant. 2021;36(1):29–38. doi:10.1093/ndt/gfaa056.
   PubMed Web of Science ®Google Scholar
• Griffin BR, Bronsert M, Reece TB, et al. Creatinine elevations from baseline at the time of cardiac surgery are associated with postoperative complications. J Thorac Cardiovasc Surg. 2022;163(4):1378–1387. doi:10.1016/j.jtcvs.2020.03.174.
   PubMed Web of Science ®Google Scholar
• STARSurg Collaborative. Perioperative intravenous contrast administration and the incidence of acute kidney injury after major gastrointestinal surgery: prospective, multicentre cohort study. J British Surgery. 2020;107(8):1023–1032. doi:10.1002/bjs.11453.
   PubMed Web of Science ®Google Scholar
• Boyd A, Brown A, Patel J, et al. Basiliximab with delayed tacrolimus improves short-term renal outcomes post-liver transplantation—a real-world experience. Transplant Proc. 2021;53(5):1541–1547. doi:10.1016/j.transproceed.2021.04.001.
   PubMed Web of Science ®Google Scholar
• Xu Y, Huang Y, Zhang C, et al. Efficacy and safety of rituximab for primary nephrotic syndrome with acute kidney injury: a two-center prospective cohort study. Clin Immunol. 2023;246:109211. doi:10.1016/j.clim.2022.109211.
   PubMed Web of Science ®Google Scholar
• Banas B, Krämer BK, Krüger B, et al. Long-Term kidney transplant outcomes: role of prolonged-release tacrolimus. Transplant Proc. 2020;52(1):102–110. doi:10.1016/j.transproceed.2019.11.003.
   PubMed Web of Science ®Google Scholar
• Curci C, Sallustio F, Serino G, et al. Potential role of effector memory T cells in chronic T cell-mediated kidney graft rejection. Nephrol Dial Transplant. 2016;31(12):2131–2142. doi:10.1093/ndt/gfw245.
   PubMed Web of Science ®Google Scholar
• Yang L, Ning Q, Tang S-S Recent advances and next breakthrough in immunotherapy for cancer treatment. J Immunol Res. 2022;2022:8052212. doi:10.1155/2022/8052212.
   PubMed Web of Science ®Google Scholar
• Miano TA, Flesch JD, Feng R, et al. Early tacrolimus concentrations after lung transplant are predicted by combined clinical and genetic factors and associated with acute kidney injury. Clin Pharmacol Ther. 2020;107(2):462–470. doi:10.1002/cpt.1629.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wei L, Guan Y, et al. Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients. Ren Fail. 2020;(1):1111–1117. doi:10.1080/0886022X.2020.1838926.
   PubMed Web of Science ®Google Scholar
• Lee CH, Gwon JG, Jung CW. Effectiveness of thymoglobulin induction therapy in kidney transplant from deceased donor with mild to moderate acute kidney injury. Transplant Proc. 2019;51(8):2611–2614. doi:10.1016/j.transproceed.2019.02.061.
   PubMed Web of Science ®Google Scholar
• Eriksson P, Wallin P, Sjöwall C. Clinical experience of sirolimus regarding efficacy and safety in systemic lupus erythematosus [original research]. Front Pharmacol. 2019;10:82. doi:10.3389/fphar.2019.00082.
   PubMed Web of Science ®Google Scholar
• Grins E, Ederoth P, Bjursten H, et al. Effect of cyclosporine on cytokine production in elective coronary artery bypass grafting: a Sub-analysis of the CiPRICS (cyclosporine to protect renal function in cardiac surgery) study. J Cardiothorac Vasc Anesth. 2022;36(7):1985–1994. doi:10.1053/j.jvca.2021.11.026.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Mueller EA, Van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation—a multicenter investigation in kidney transplant patients. Transplantation. 1994;58(6):663. doi:10.1097/00007890-199409000-00004.
   PubMed Web of Science ®Google Scholar
• Tremblay S, Nigro V, Weinberg J, et al. A Steady-State head-to-Head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): an Open-Label, prospective, randomized, two-Arm, Three-Period crossover study. Am J Transplant. 2017;17(2):432–442. doi:10.1111/ajt.13935.
   PubMed Web of Science ®Google Scholar
• Zwart TC, Bezstarosti S, Achini FR, et al. Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation. Br J Clin Pharmacol. 2023;89(4):1471–1485. doi:10.1111/bcp.15608.
   PubMed Web of Science ®Google Scholar
• Grim J, Chládek J, Martínková J. Pharmacokinetics and pharmacodynamics of methotrexate in non-Neoplastic diseases. Clin Pharmacokinet. 2003;42(2):139–151. doi:10.2165/00003088-200342020-00003.
   PubMed Web of Science ®Google Scholar
• Patocka J, Nepovimova E, Kuca K, et al. Cyclosporine A: chemistry and toxicity–a review. Curr Med Chem. 2021;28(20):3925–3934.
   PubMed Web of Science ®Google Scholar
• Ederoth P, Dardashti A, Grins E, et al. Cyclosporine before coronary artery bypass grafting does not prevent postoperative decreases in renal function: a randomized clinical trial. J. Anesthesiology. 2018;128(4):710–717. doi:10.1097/ALN.0000000000002104.
   PubMed Web of Science ®Google Scholar
• Wu Q, Wang X, Nepovimova E, et al. Mechanism of cyclosporine a nephrotoxicity: oxidative stress, autophagy, and signalings. Food Chem Toxicol. 2018;118:889–907. doi:10.1016/j.fct.2018.06.054.
   PubMed Web of Science ®Google Scholar
• Rao S, Bernshteyn M, Sohal R, et al. The management of erythrodermic psoriasis complicated by cyclosporine. Case Rep Dermatol Med. 2020;2020:5215478. doi:10.1155/2020/5215478.
   PubMedGoogle Scholar
• Goździk M, Płuciennik A, Zawiasa-Bryszewska A, et al. Acute kidney injury following exposure to calcineurin inhibitors in a patient with idiopathic membranous nephropathy. Drug Saf Case Rep. 2019;6(1):9. doi:10.1007/s40800-019-0103-x.
   PubMedGoogle Scholar
• Bacle A, Lhermitte R, Le DB, et al. Unexpected overdose of oral cyclosporine in a kidney transplant patient: a case report. Eur J Hosp Pharm. 2023;30(4):242–244. doi:10.1136/ejhpharm-2021-002730.
   PubMedGoogle Scholar
• D’Oria R, Schipani R, Leonardini A, et al. The role of oxidative stress in cardiac disease: from physiological response to injury factor. Oxid Med Cell Longev. 2020;2020:5732929–5732956. doi:10.1155/2020/5732956.
   Web of Science ®Google Scholar
• Karimzadeh I, Jafari M, Davani-Davari D, et al. The pattern of cyclosporine nephrotoxicity and urinary kidney injury molecule 1 in allogenic hematopoietic stem cell transplant patients. Exp Clin Transplant. 2020;19(6):553–562. doi:10.6002/ect.2020.0123.
   PubMed Web of Science ®Google Scholar
• Ramírez-Bajo MJ, Martín-Ramírez J, Bruno S, et al. Nephroprotective potential of mesenchymal stromal cells and their extracellular vesicles in a murine model of chronic cyclosporine nephrotoxicity. Front Cell Dev Biol. 2020;8:296. doi:10.3389/fcell.2020.00296.
   PubMed Web of Science ®Google Scholar
• Broen JCA, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol. 2020;16(3):167–178. doi:10.1038/s41584-020-0374-8.
   PubMed Web of Science ®Google Scholar
• Sallustio BC. Monitoring intra-cellular tacrolimus concentrations in solid organ transplantation: use of peripheral blood mononuclear cells and graft biopsy tissue. Front Pharmacol. 2021;12:733285. doi:10.3389/fphar.2021.733285.
   PubMed Web of Science ®Google Scholar
• Nakata S, Kakimoto K, Numa K, et al. Risk factors for nephrotoxicity due to tacrolimus therapy for ulcerative colitis. Digestion. 2022;103(5):339–346. doi:10.1159/000524594.
   PubMed Web of Science ®Google Scholar
• Bentata Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs. 2020;44(2):140–152. doi:10.1111/aor.13551.
   PubMed Web of Science ®Google Scholar
• Claeys E, Vermeire K. Immunosuppressive drugs in organ transplantation to prevent allograft rejection: mode of action and side effects. J Immunological Sci. 2019;3(4):14–21. doi:10.29245/2578-3009/2019/4.1178.
   Google Scholar
• Sprangers B, Decoo D, Dive D, et al. Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus. Acta Neurol Belg. 2018;118(2):143–151. doi:10.1007/s13760-017-0864-x.
   PubMed Web of Science ®Google Scholar
• Harrigan AM, West ML, Geldenhuys L, et al. Renal-Limited antiglomerular basement membrane disease related to alemtuzumab: a case report. Can J Kidney Health Dis. 2020;7. doi:10.1177/2054358120962680.
   PubMedGoogle Scholar
• Chazin S, Saqqa O, Paramesh A, et al. Skin lesions and acute kidney injury in a kidney transplant recipient. Am J Transplant. 2021;21(6):2298–2300. doi:10.1111/ajt.16519.
   Web of Science ®Google Scholar
• Liou AA, Skiver BM, Yates E, et al. Acute thrombotic microangiopathy and cortical necrosis following administration of alemtuzumab: a case report. Am J Kidney Dis. 2019;73(5):615–619. doi:10.1053/j.ajkd.2018.09.013.
   PubMed Web of Science ®Google Scholar
• Guthoff M, Berger K, Althaus K, et al. Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients. BMC Nephrol. 2020;21(1):178. doi:10.1186/s12882-020-01767-z.
   PubMed Web of Science ®Google Scholar
• van der Zwan M, Clahsen-Van Groningen MC, van den Hoogen MWF, et al. Comparison of alemtuzumab and anti-thymocyte globulin treatment for acute kidney allograft rejection. Front Immunol. 2020;11:1332. doi:10.3389/fimmu.2020.01332.
   PubMed Web of Science ®Google Scholar
• Saulite I, Guenova E, Hoetzenecker W. Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab. Curr Probl Dermatol. 2018;53:70–81. doi:10.1159/000478079.
   Google Scholar
• Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145–154. doi:10.1038/s41584-020-0373-9.
   PubMed Web of Science ®Google Scholar
• Amitai I, Rozovski U, El-Saleh R, et al. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. Hematol Oncol. 2020;38(4):584–588. doi:10.1002/hon.2759.
   PubMed Web of Science ®Google Scholar
• Jessel S, Austin M, Kluger HM. Mycophenolate as primary treatment for immune checkpoint inhibitor induced acute kidney injury in a patient with concurrent immunotherapy-associated diabetes. Clin Oncol Case Rep 156. Eng.
   Google Scholar
• Liang CA, Su YC, Lin SJ, et al. Risk factors for acute kidney injury after high-dose methotrexate therapy: a single-center study and narrative review. Eur J Clin Pharmacol. 2023;79(6):789–800. doi:10.1007/s00228-023-03491-7.
   PubMed Web of Science ®Google Scholar
• Attias P, Melica G, Boutboul D, et al. Epidemiology, risk factors, and outcomes of opportunistic infections after kidney allograft transplantation in the era of modern immunosuppression: a monocentric cohort study. J Clin Med. 2019;8(5):594. doi:10.3390/jcm8050594.
   PubMed Web of Science ®Google Scholar
• Sami FL, Hammo H, Athavale A. Crystalline nephropathy with high-dose methotrexate in a patient with primary CNS lymphoma: a case report. Cureus. 2022;14(6):e26052. doi:10.7759/cureus.26052.
   PubMed Web of Science ®Google Scholar
• Kawano N, Matsumoto K, Takami A, et al. Pharmacokinetics of anti-thymocyte globulin in a patient with severe aplastic anemia treated with allogeneic bone marrow transplantation from a matched unrelated donor. (2432-7026 (Electronic)). eng.
   Google Scholar
• Kovarik JM, Nashan B, Neuhaus P, et al. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin Pharmacol Ther. 2001;69(4):201–209. doi:10.1067/mcp.2001.114887.
   PubMed Web of Science ®Google Scholar
• Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol. 2005;45(5):490–497. doi:10.1177/0091270004273321.
   PubMed Web of Science ®Google Scholar
• Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645–660. doi:10.2165/00003088-200746080-00002.
   PubMed Web of Science ®Google Scholar
• Toapanta N, Jiménez S, Molina-Gómez M, et al. Induction immunosuppression and outcome in kidney transplant recipients with early COVID-19 after transplantation. Clin Kidney J. 2022;15(11):2039–2045. doi:10.1093/ckj/sfac112.
   PubMed Web of Science ®Google Scholar
• Hamed KM, Dighriri IM, Baomar AF, et al. Overview of methotrexate toxicity: a comprehensive literature review. Cureus. 2022;14(9):e29518. doi:10.7759/cureus.29518.
   PubMed Web of Science ®Google Scholar
• Juliette R, Pierre-Joseph R, Gwenaëlle E, et al. LIS1, a glyco-humanized swine polyclonal anti-lymphocyte globulin, as a novel induction treatment in solid organ Transplantation. 2022; bioRxiv. doi:10.1101/2022.09.08.507114.
   Google Scholar
• Akl A, Alobaidi S, Aboalsamh G. Living-Donor kidney transplant-associated thrombotic microangiopathy successfully treated with thymoglobulin: a case report. Exp Clin Transplant. 2019;17(Suppl 1):175–177. doi:10.6002/ect.MESOT2018.P51.
   PubMedGoogle Scholar
• Ducloux D, Kazory A, Challier B, et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation. 2004;77(7):1029–1033. doi:10.1097/01.tp.0000116442.81259.60.
   PubMed Web of Science ®Google Scholar
• Mo XD, Hong SD, Zhao YL, et al. Basiliximab for steroid-refractory acute graft-versus-host disease: a real-world analysis. Am J Hematol. 2022;97(4):458–469. doi:10.1002/ajh.26475.
   PubMed Web of Science ®Google Scholar
• Seo Y, Geum MJ, Lee KA, et al. Medication utilization analysis of basiliximab as a maintenance immunosuppressant in renal failure patients undergoing lung transplantation. Korean J Clin Pharm. 2020;30(3):149–160. doi:10.24304/kjcp.2020.30.3.149.
   Google Scholar
• Kim KD, Lee KW, Kim SJ, et al. Safety and effectiveness of kidney transplantation using a donation after brain death donor with acute kidney injury: a retrospective cohort study. Sci Rep. 2021;11(1):5572. doi:10.1038/s41598-021-84977-1.
   PubMed Web of Science ®Google Scholar
• Kim HE, Paik HC, Jeong SJ, et al. Basiliximab induction with delayed calcineurin inhibitors for high-risk lung transplant candidates. Yonsei Med J. 2021;62(2):164–171. doi:10.3349/ymj.2021.62.2.164.
   PubMed Web of Science ®Google Scholar
• Bennett D, Fossi A, Marchetti L, et al. Postoperative acute kidney injury in lung transplant recipients. Interact Cardiovasc Thorac Surg. 2019;28(6):929–935. doi:10.1093/icvts/ivy355.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Park BS, Park S, et al. Basiliximab-Induced non-cardiogenic pulmonary edema in a kidney transplant patient. Korean J Transplant. 2018;32(3):63–68. doi:10.4285/jkstn.2018.32.3.63.
   Google Scholar
• Ammar A, Zafar Ahmed Mahmood H, Shahid Z, et al. Etanercept-associated nephropathy. Cureus. 2019;11(8):e5419. doi:10.7759/cureus.5419.
   PubMed Web of Science ®Google Scholar
• Xu YL, Zou P, Cao XJ. Advances in pharmacotherapy for acute kidney injury. Expert Opin Pharmacother. 2022;23(6):713–726. doi:10.1080/14656566.2022.2050214.
   PubMed Web of Science ®Google Scholar
• Abdelmageed MM, Kefaloyianni E, Arthanarisami A, et al. TNF or EGFR inhibition equally block AKI-to-CKD transition: opportunities for etanercept treatment. Nephrol Dial Transplant. 2023;38(5):1139–1150. doi:10.1093/ndt/gfac290.
   PubMed Web of Science ®Google Scholar
• Miao X, Huang Y, Liu T-T, et al. TNF-α/TNFR1 signaling is required for the full expression of acute and chronic itch in mice via peripheral and Central mechanisms. Neurosci Bull. 2018;34(1):42–53. doi:10.1007/s12264-017-0124-3.
   PubMed Web of Science ®Google Scholar
• McCoy IE, Hsu JY, Bonventre JV, et al. Acute kidney injury associates with long-term increases in plasma TNFR1, TNFR2, and KIM-1: findings from the CRIC study. JASN. 2022;33(6):1173–1181. doi:10.1681/ASN.2021111453.
   Web of Science ®Google Scholar
• Feist E, Baraliakos X, Behrens F, et al. Effectiveness of etanercept in rheumatoid arthritis: real-world data from the German non-interventional study ADEQUATE with focus on treat-to-Target and patient-reported outcomes. Rheumatol Ther. 2022;9(2):621–635. doi:10.1007/s40744-021-00418-5.
   PubMed Web of Science ®Google Scholar
• Subedi S, Gong Y, Chen Y, et al. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. Drug Des Devel Ther. 2019;13:2491–2502. doi:10.2147/DDDT.S200147.
   PubMed Web of Science ®Google Scholar
• Melsheimer R, Geldhof A, Apaolaza I, et al. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics. 2019;13:139–178. doi:10.2147/BTT.S207246.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Fan R, Botchway BOA, et al. Infliximab can improve traumatic brain injury by suppressing the tumor necrosis factor alpha pathway. Mol Neurobiol. 2021;58(6):2803–2811. doi:10.1007/s12035-021-02293-1.
   PubMed Web of Science ®Google Scholar
• Lin JS, Mamlouk O, Selamet U, et al. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology. 2021;10(1):1877415. doi:10.1080/2162402X.2021.1877415.
   PubMed Web of Science ®Google Scholar
• Ozdemir A, Tumkaya L, Kalcan S, et al. The effects of TNF-alpha inhibitors on carbon tetrachloride-induced nephrotoxicity. Clin Exp Hypertens. 2022;44(3):291–296. doi:10.1080/10641963.2021.2018600.
   PubMed Web of Science ®Google Scholar
• Hsieh C-Y, Tsai T-F. Drug-induced neutropenia during treatment of non-Neoplastic dermatologic diseases: a review. Clin Drug Investig. 2020;40(10):915–926. doi:10.1007/s40261-020-00956-w.
   PubMed Web of Science ®Google Scholar
• Gibson DJ, Ward MG, Rentsch C, et al. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;51(6):612–628. doi:10.1111/apt.15643.
   PubMed Web of Science ®Google Scholar
• Hasskarl J. Everolimus. Recent Results Cancer Res. 2018;211:101–123. doi:10.1007/978-3-319-91442-8_8.
   PubMedGoogle Scholar
• Desai V, Thakkar J, Wanchoo R, et al. 17 Targeted cancer therapies. Onco-Nephrology E-Book. 2019;:154.
   Google Scholar
• Kadry Z, Stine JG, Dohi T, et al. Renal protective effect of everolimus in liver transplantation: a prospective randomized Open-Label trial. Transplant Direct. 2021;7(7):e709. doi:10.1097/TXD.0000000000001159.
   PubMed Web of Science ®Google Scholar
• López FN, Alfocea PA, Suazo EJO, et al. Impact of everolimus-based immunosuppression on renal function in liver transplant recipients. Transplantation Proceedings. 2020.
   Google Scholar
• Shoji MK, Shishido S, Freitag SK. The use of sirolimus for treatment of orbital lymphatic malformations: a systematic review. Ophthalmic Plast Reconstr Surg. 2020;36(3):215–221. doi:10.1097/IOP.0000000000001518.
   PubMed Web of Science ®Google Scholar
• Newitt VN. UCSF oncologist strives to stem the rise of cancer in Tanzania. Oncology Times. 2023;21:21,22,29.
   Google Scholar
• Xu KY, Shameem R, Wu S. Risk of hyperglycemia attributable to everolimus in cancer patients: a meta-analysis. Acta Oncol. 2016; 55(9–10):1196–1203. doi:10.3109/0284186X.2016.1168939.
   PubMed Web of Science ®Google Scholar
• Tedesco‐Silva H, del Carmen Rial M, Cruz Santiago J, et al. Optimizing the clinical utility of sirolimus‐based immunosuppression for kidney transplantation. Clin Transplant. 2019;33(2):e13464. doi:10.1111/ctr.13464.
   PubMed Web of Science ®Google Scholar
• Tsai KF, Li LC, Hsu CN, et al. Effects of conversion from calcineurin inhibitors to sirolimus or everolimus on renal function and possible mechanisms in liver transplant recipients. J Clin Pharmacol. 2019;59(3):326–334. doi:10.1002/jcph.1334.
   PubMed Web of Science ®Google Scholar
• Nguyen LS, Vautier M, Allenbach Y, et al. Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation. Drug Saf. 2019;42(7):813–825. doi:10.1007/s40264-019-00810-9.
   PubMed Web of Science ®Google Scholar
• Paluri RK, Sonpavde G, Morgan C, et al. Renal toxicity with mammalian target of rapamycin inhibitors: a meta-analysis of randomized clinical trials. Oncol Rev. 2019;13(2):455. doi:10.4081/oncol.2019.455.
   PubMed Web of Science ®Google Scholar
• Saggi SJ, Nath S, Culas R, et al. Early experience with methylprednisolone on SARS-CoV-2 infection in the African American population, a retrospective analysis. Clin Med Insights Circ Respir Pulm Med. 2020;14. doi:10.1177/1179548420980699.
   PubMed Web of Science ®Google Scholar
• Garg AX, Chan MTV, Cuerden MS, et al. Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with a cardiopulmonary bypass pump: a randomized controlled trial. CMAJ. 2019;191(9):E247–E256. doi:10.1503/cmaj.181644.
   PubMed Web of Science ®Google Scholar
• Sakemi T, Yamaguchi M, Fujimi S, et al. Effects of the methylprednisolone pulse therapy on renal function. Am J Nephrol. 1991;11(1):48–53. doi:10.1159/000168272.
   PubMed Web of Science ®Google Scholar
• Fouad D, Shuker E, Farhood M. Renal toxicity of methylprednisolone in male Wistar rats and the potential protective effect by boldine supplementation. J King Saud Unive Sci. 2023;35(1):102381. doi:10.1016/j.jksus.2022.102381.
   Web of Science ®Google Scholar
• Dumortier J, Cottin J, Lavie C, et al. Methylprednisolone liver toxicity: a new case and a French regional pharmacovigilance survey. Clin Res Hepatol Gastroenterol. 2017;41(4):497–501. doi:10.1016/j.clinre.2017.03.008.
   PubMed Web of Science ®Google Scholar
• Sajgure A, Kulkarni A, Joshi A, et al. Safety and efficacy of mycophenolate in COVID-19: a nonrandomised prospective study in Western India. Lancet Reg Health Southeast Asia. 2023;11:100154. doi:10.1016/j.lansea.2023.100154.
   PubMedGoogle Scholar
• Nakano K, Nishizawa M, Fukuda N, et al. Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis. Oxf Med Case Reports. 2020;2020(4):omaa027. doi:10.1093/omcr/omaa027.
   PubMedGoogle Scholar
• Alam A, Van Zyl JS, Hall SA, et al. Impact of risk-stratified mycophenolate dosing in heart transplantation. Clin Transplant. 2021;35(11):e14445. doi:10.1111/ctr.14445.
   PubMed Web of Science ®Google Scholar
• Stoleru G, Bhattacharya S, Patel P, et al. S3308 characterization of mycophenolate mofetil gastrointestinal toxicity and risk factors for severe disease and poor prognosis. Am J Gastroenterol. 2021;116(1):S1363–S1364. doi:10.14309/01.ajg.0000786764.63177.77.
   PubMedGoogle Scholar
• Kiang TKL, Ensom MHH. Exposure-toxicity relationships of mycophenolic acid in adult kidney transplant patients. Clin Pharmacokinet. 2019;58(12):1533–1552. doi:10.1007/s40262-019-00802-z.
   PubMed Web of Science ®Google Scholar
• Siewe N, Friedman A. Cancer therapy with immune checkpoint inhibitor and CSF-1 blockade: a mathematical model. J Theor Biol. 2023;556:111297. doi:10.1016/j.jtbi.2022.111297.
   PubMed Web of Science ®Google Scholar
• Pal SK, Albiges L, Tomczak P, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet. 402(10397):185–195. doi:10.1016/S0140-6736(23)00922-4.
   PubMed Web of Science ®Google Scholar
• Garcia P, Stedman MR, Merlo S, et al. Kidney function while on immune checkpoint inhibitors: trends in incidence of acute kidney injury, and its causes and outcomes. J Onco-Nephrol. 2023;7(2):57–65. doi:10.1177/23993693231161875.
   Google Scholar
• Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21(7):509–528. doi:10.1038/s41573-021-00345-8.
   PubMed Web of Science ®Google Scholar
• Abdelrahim M, Mamlouk O, Lin H, et al. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis. OncoImmunology. 2021;10(1):1927313. doi:10.1080/2162402X.2021.1927313.
   PubMed Web of Science ®Google Scholar
• Lemoine M, Dilly B, Curie A, et al. Ipilimumab-induced renal granulomatous arteritis: a case report. BMC Nephrol. 2019;20(1):366. doi:10.1186/s12882-019-1552-2.
   PubMed Web of Science ®Google Scholar
• Person F, Chahoud-Schriefer T, Fehrle W, et al. Severe acute kidney injury due to nivolumab/ipilimumab-induced granulomatosis and fibrinoid vascular necrosis. J Immunother. 2020;43(1):29–31. doi:10.1097/Cji.0000000000000296.
   PubMed Web of Science ®Google Scholar
• Gebauer E, Bechtel-Walz W, Schell C, et al. Development of nivolumab/Ipilimumab-Associated autoimmune nephritis during steroid therapy. Case Rep Nephrol Dial. 2021;11(3):270–274. doi:10.1159/000517502.
   PubMed Web of Science ®Google Scholar
• Biewenga M, van der Kooij MK, Wouters MWJM, et al. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. Hepatol Int. 2021;15(2):510–519. doi:10.1007/s12072-021-10151-4.
   PubMed Web of Science ®Google Scholar
• Tsui E, Gonzales JA. Retinal vasculitis associated with ipilimumab. Ocul Immunol Inflamm. 2020;28(6):868–870. doi:10.1080/09273948.2019.1610460.
   PubMed Web of Science ®Google Scholar
• Domenico M, Diana G, Maria Grazia V, et al. Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis. J ImmunoTher Cancer. 2022;10(11):e005132. doi:10.1136/jitc-2022-005132.
   PubMed Web of Science ®Google Scholar
• Okawa S, Fujiwara K, Shimonishi A, et al. Rapidly progressive acute kidney injury associated with nivolumab treatment. Case Rep Oncol. 2020;13(1):85–90. doi:10.1159/000505235.
   PubMed Web of Science ®Google Scholar
• Ryuzaki M, Tokuyama H, Uchiyama K, et al. Acute interstitial nephritis with karyomegalic epithelial cells after nivolumab treatment—two case reports. Clinical Med Insights: Case Report. 2019;12:1179547619853647.
   Web of Science ®Google Scholar
• Cruz-Whitley J, Giehl N, Jen K-Y, et al. Membranoproliferative glomerulonephritis associated with nivolumab therapy. Case Rep Nephrol. 2020;:2638283–2638284. doi:10.1155/2020/2638283.
   PubMedGoogle Scholar
• Yamada H, Okajima F, Onda T, et al. New-onset graves’ disease after the initiation of nivolumab therapy for gastric cancer: a case report. BMC Endocr Disord. 2020;20(1):132. doi:10.1186/s12902-020-00613-5.
   PubMed Web of Science ®Google Scholar
• Tanaka R, Maruyama H, Tomidokoro Y, et al. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset guillain–barré syndrome: a case report. Jpn J Clin Oncol. 2016;46(9):875–878. doi:10.1093/jjco/hyw090.
   PubMed Web of Science ®Google Scholar
• Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–742.
   PubMed Web of Science ®Google Scholar
• Bonilla M, Bijol V, Corona AGDL, et al. A case of immune-complex mediated glomerulonephritis associated with pembrolizumab. J Onco-Nephrol. 2021;6(1–2):79–83. doi:10.1177/23993693211064627.
   Google Scholar
• Basnet S, Dhital R, Tharu B. Acute tubulointerstitial nephritis: a case report on rare adverse effect of pembrolizumab. Medicina (Kaunas). 2019;55(5):176. doi:10.3390/medicina55050176.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Mathian A, Champiat S, et al. Renal toxicities associated with pembrolizumab. Clin Kidney J. 2019;12(1):81–88. doi:10.1093/ckj/sfy100.
   PubMed Web of Science ®Google Scholar
• Ishibuchi K, Iwakura T, Kaneko M, et al. Pembrolizumab-associated nephrotic syndrome recovered from transient hemodialysis in a patient with lung cancer. CEN Case Rep. 2020;9(3):215–219. doi:10.1007/s13730-020-00462-0.
   PubMed Web of Science ®Google Scholar
• De Giglio A, Grandinetti V, Aprile M, et al. Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): a single-center experience. Lung Cancer. 2022;174:91–96. doi:10.1016/j.lungcan.2022.10.007.
   PubMed Web of Science ®Google Scholar
• Dalvin LA, Shields CL, Orloff M, et al. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063–1078. doi:10.1097/IAE.0000000000002181.
   PubMed Web of Science ®Google Scholar
• OConnor C, Jordan E, O’Connell M. Atypical stevens–johnson syndrome caused by pembrolizumab in the treatment of metastatic melanoma: are corticosteroids a safe treatment option? J Dermatol Dermatol Surg. 2020;24/(2):137. doi:10.4103/jdds.jdds_73_20.
   Web of Science ®Google Scholar
• Zakharova E, Makarova T, Vorobyeva OA. Case of atezolizumab-associated tubulointerstitial nephritis. Journal of Onco-Nephrology. 2022;6(1-2):56–58. doi:10.1177/23993693221080479.
   Google Scholar
• Izzedine H, Mathian A, Albiges L, et al. Association of thrombotic microangiopathy with atezolizumab therapy in cancer patients. Eur J Cancer. 2021;149:34–36. doi:10.1016/j.ejca.2021.02.033.
   PubMed Web of Science ®Google Scholar
• Taki T, Oda N, Fujioka Y, et al. Successful treatment of non-small-cell lung cancer with atezolizumab following tubulointerstitial nephritis due to pembrolizumab. Intern Med. 2020;59(13):1639–1642. doi:10.2169/internalmedicine.4260-19.
   PubMed Web of Science ®Google Scholar
• Kawataki M, Nakanishi Y, Yokoyama T, et al. Hypothyroidism as an immune-related adverse event caused by atezolizumab in a patient with muscle spasms: a case report. Respir Med Case Rep. 2022. doi:10.1016/j.rmcr.2022.101585.
   PubMed Web of Science ®Google Scholar
• Syed YY. Durvalumab: first global approval. Drugs. 2017;77(12):1369–1376. doi:10.1007/s40265-017-0782-5.
   PubMed Web of Science ®Google Scholar
• Janagam P. Durvalumab-Induced iga nephropathy in stage iii non-small cell lung cancer after chemoradiation. Chest. 2021;60(4):A1578. doi:10.1016/j.chest.2021.07.1443.
   Google Scholar
• Swanson LA, Kassab I, Tsung I, et al. Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: a retrospective analysis. Front Oncol. 2022;12:984940. doi:10.3389/fonc.2022.984940.
   PubMed Web of Science ®Google Scholar